Ali, I.; Haq, I.U.; Imtiaz, N.; Iqbal, M.N.; Rahman, R.U.; Alonazi, W.B.; Rasheed, M.A. Computational Exploration and Molecular Dynamic Simulation for the Discovery of Antiviral Agents Targeting Newcastle Disease Virus. Preprints2024, 2024030457. https://doi.org/10.20944/preprints202403.0457.v1
APA Style
Ali, I., Haq, I.U., Imtiaz, N., Iqbal, M.N., Rahman, R.U., Alonazi, W.B., & Rasheed, M.A. (2024). Computational Exploration and Molecular Dynamic Simulation for the Discovery of Antiviral Agents Targeting Newcastle Disease Virus. Preprints. https://doi.org/10.20944/preprints202403.0457.v1
Chicago/Turabian Style
Ali, I., Wadi B. Alonazi and Muhammad Asif Rasheed. 2024 "Computational Exploration and Molecular Dynamic Simulation for the Discovery of Antiviral Agents Targeting Newcastle Disease Virus" Preprints. https://doi.org/10.20944/preprints202403.0457.v1
Abstract
Newcastle disease (ND) is a viral infection that affects domestic and wild type birds especially poultry and establishing serious economic costs for poultry industry. Newcastle disease virus’ (NDV) HN membrane receptor is attractive therapeutic candidate, contributes to pathogenicity with various functions such as fusion and prevent viral self-agglutination to permit viral spread. No validated HN inhibitor has been reported yet. However, the purpose of current study was to determine potential compounds via pharmacophore-based screening of natural molecules to inhibit HN receptor of NDV. Physicochemical characteristics and phylogenetic analysis were determined to elucidate structural information and phylogeny of target protein across different species as well as members of gene family. Fill missing residues of HN target protein and evaluated via PROCHECK and VERIFY 3D. We employed shape and feature-based pharmacophore model and screen natural compound’s library through numerous scoring schemes. Top 48 hits with 0.8860 pharmacophore fit score were subjected towards structure-based molecular docking. Top 9 compounds was observed witihin the range of -8.9 to -7.5 kcal/mol binding score. Five best-fitting compounds in complex with HN receptor were subjected to predict biological activity and ADMET analysis. Top two hits were selected for MD simulations to validate binding modes and structural stability. Upon scrutinization, A1 (ZINC05223166) emerges as potential HN inhibitor to treat ND, necessitating further validation via clinical trials.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
,
